The advent of targeted cancer therapies has necessitated the development of companion diagnostics to identify those patients whose genetic makeup will allow them to benefit. But a patient’s gene signature is only one factor of many capable of affecting their response to a treatment.
There is a demand, says Mohammad Afshar, CEO of Ariana Pharma, for a tool that will analyse all of a patient’s characteristics at once – physiological, genetic, genomic, proteomic – and assign them the drug or procedure that will benefit them most. He tells EP Vantage: “What we’re working on here is the ability to look at all the data that is available on these particular tumours and patients, and combine this information together to identify the best treatment.”
Read the full EP Vantage interview with Mohammad Afshar online, or download the PDF.